Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Arthritis
Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
May 9th, 2008
Latona Life Sciences Inc. (Latona) announced that it has entered into two agreements for the acquisition of patent rights and orphan drug status to a novel late-stage drug, trademarked "Oralgam," for the treatment of Juvenile and Adult Rheumatoid Arthritis. Latona has entered into a licensing agreement to acquire the patent rights to Oralgam with Research Corporation Technologies, Inc., of Tucson, Arizona. Under the terms of this agreement, Latona will acquire the exclusive worldwide rights to Oralgam for the treatment of Adult Rheumatoid Arthritis and the treatment of auto-immune induced hearing loss. Latona has also entered into a purchase and sale...
Source: Health Business Week (2008-05-09)
|
